Evonik Evonik

X
[{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Revatis SA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Discovery"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"EXO Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genflow Biosciences Partners with Revatis SA and EXO Biologics in Groundbreaking Aging Research, Fueled by Two Major Research Grants","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Preclinical"}]

Find Clinical Drug Pipeline Developments & Deals by Genflow Biosciences

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            This collaborative effort aims to expand and diversify Genflow's research pipeline for conditions such as Sarcopenia, the progressive loss of muscle mass and function associated with ageing.

            Lead Product(s): Undisclosed

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Revatis SA

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 18, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            This collaboration aims to develop a novel mRNA delivery system using exosomes to encapsulate and transport Genflow’s proprietary centenarian SIRT6 gene to revolutionize therapeutic interventions including GF-3001 for Werner Syndrome.

            Lead Product(s): GF-3001

            Therapeutic Area: Genetic Disease Product Name: GF-3001

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: EXO Biologics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 18, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY